CA2909418A1 - Ester derivative of 7-.alpha.-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)n onyl]-estra-1,3,5(10)-triene-3,17.beta.-diol having anticancer activity and preparation method thereof - Google Patents

Ester derivative of 7-.alpha.-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)n onyl]-estra-1,3,5(10)-triene-3,17.beta.-diol having anticancer activity and preparation method thereof

Info

Publication number
CA2909418A1
CA2909418A1 CA2909418A CA2909418A CA2909418A1 CA 2909418 A1 CA2909418 A1 CA 2909418A1 CA 2909418 A CA2909418 A CA 2909418A CA 2909418 A CA2909418 A CA 2909418A CA 2909418 A1 CA2909418 A1 CA 2909418A1
Authority
CA
Canada
Prior art keywords
compound
formula
substituent
ethylpyridine
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2909418A
Other languages
English (en)
French (fr)
Inventor
Yaqi Jiao
Jiucheng Wang
Renle Hu
Original Assignee
Xian Libang Pharmaceutical Technology Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Xian Libang Pharmaceutical Technology Co Ltd filed Critical Xian Libang Pharmaceutical Technology Co Ltd
Publication of CA2909418A1 publication Critical patent/CA2909418A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J31/00—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring
    • C07J31/006—Normal steroids containing one or more sulfur atoms not belonging to a hetero ring not covered by C07J31/003
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified
    • C07J1/0074—Esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J1/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • C07J1/0051—Estrane derivatives
    • C07J1/0066—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa
    • C07J1/007—Estrane derivatives substituted in position 17 beta not substituted in position 17 alfa the substituent being an OH group free esterified or etherified

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Steroid Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CA2909418A 2013-04-18 2013-04-18 Ester derivative of 7-.alpha.-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)n onyl]-estra-1,3,5(10)-triene-3,17.beta.-diol having anticancer activity and preparation method thereof Abandoned CA2909418A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/CN2013/074363 WO2014169462A1 (zh) 2013-04-18 2013-04-18 具有抗癌活性的7-α-[9-(4,4,5,5,-五氟戊基亚硫酰基)壬基]-雌甾-1,3,5(10)-三烯-3,17β-二醇的酯类衍生物及其制备方法

Publications (1)

Publication Number Publication Date
CA2909418A1 true CA2909418A1 (en) 2014-10-23

Family

ID=51730699

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2909418A Abandoned CA2909418A1 (en) 2013-04-18 2013-04-18 Ester derivative of 7-.alpha.-[9-(4,4,5,5,5-pentafluoropentylsulfinyl)n onyl]-estra-1,3,5(10)-triene-3,17.beta.-diol having anticancer activity and preparation method thereof

Country Status (8)

Country Link
US (1) US20160060288A1 (https=)
EP (1) EP2987799B1 (https=)
JP (1) JP6356218B2 (https=)
KR (1) KR102046415B1 (https=)
CN (1) CN104936971B (https=)
AU (1) AU2013386732B2 (https=)
CA (1) CA2909418A1 (https=)
WO (1) WO2014169462A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014169456A1 (zh) * 2013-04-18 2014-10-23 西安力邦医药科技有限责任公司 7-α-[9-(4,4,5,5,5-五氟戊基亚硫酰基)壬基]-雌甾-1,3,5(10)-三烯-3,17β-二醇及其衍生物的用途
JP7384903B2 (ja) * 2018-05-24 2023-11-21 ケーアイ ファーマシューティカルズ，リミテッド・ライアビリティ・カンパニー フルベストラントのプロドラッグ
EP4061376A4 (en) * 2019-11-24 2024-03-13 Kashiv Biosciences, LLC Prodrugs of fulvestrant

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7613248A (nl) * 1976-11-26 1978-05-30 Akzo Nv Werkwijze voor het bereiden van nieuwe steroid- esters.
GB8327256D0 (en) * 1983-10-12 1983-11-16 Ici Plc Steroid derivatives
US5183514A (en) 1991-04-01 1993-02-02 Texaco Chemical Company Process for dissolving or removing rigid polyurethane foam by contacting with 1,2-dimethyl imidazole
DE4218743C2 (de) * 1992-06-04 2001-10-25 Schering Ag Verfahren zur Herstellung C(7)-substituierter Estra-1,3,5(10)-triene sowie neue Ausgangsprodukte für dieses Verfahren
IL112778A0 (en) * 1994-03-04 1995-05-26 Merck & Co Inc Substituted heterocycles, their preparation and pharmaceutical compositions containing them
DE19635525A1 (de) * 1996-08-20 1998-02-26 Schering Ag 7alpha-(xi-Aminoalkyl)-estratriene, Verfahren zu deren Herstellung, pharmazeutische Präparate, die diese 7alpha(xi-Aminoalkyl-estratriene enthalten sowie deren Verwendung zur Herstellung von Arzneimitteln
AR015500A1 (es) * 1997-12-23 2001-05-02 Schering Ag 11 BETA-HALoGENO-ESTRATRIENOS SUSTITUIDOS EN 7 ALFA, PROCEDIMIENTO PARA ELABORAR PREPARADOS FARMACEUTICOS QUE CONTIENEN TALES 11 BETA-HALOGENO-ESTRATRIENOSSUSTITUIDOS EN 7 ALFA, ASI COMO SU UTILIZACION EN LA ELABORACION DE MEDICAMENTOS.
GB0000313D0 (en) 2000-01-10 2000-03-01 Astrazeneca Uk Ltd Formulation
JP2005524630A (ja) * 2002-01-14 2005-08-18 ノルディック・ビオサイエンス・エー／エス エストロゲン受容体を介する軟骨破壊の抑制
CN100395259C (zh) * 2004-04-28 2008-06-18 江苏豪森药业股份有限公司 甾体类衍生物
US7790910B2 (en) * 2004-07-27 2010-09-07 Sicor Inc. Process for the preparation of 7α-alkylated 19-norsteroids
US10174070B2 (en) * 2005-09-30 2019-01-08 Endece Llc 6-substituted estradiol derivatives and methods of use
JP5256042B2 (ja) * 2005-11-22 2013-08-07 インサイト・コーポレイション 癌の処置のための併用療法
JP2011514349A (ja) * 2008-03-07 2011-05-06 サイドース・エルエルシー フルベストラント配合物
CN102600073B (zh) * 2012-03-31 2014-01-01 莱普德制药有限公司 以乳酸酯为基础的氟维司群或其衍生物油性制剂及其制备方法
WO2014169456A1 (zh) * 2013-04-18 2014-10-23 西安力邦医药科技有限责任公司 7-α-[9-(4,4,5,5,5-五氟戊基亚硫酰基)壬基]-雌甾-1,3,5(10)-三烯-3,17β-二醇及其衍生物的用途
US9271990B2 (en) * 2014-02-14 2016-03-01 Fresenius Kabi Usa, Llc Fulvestrant formulations

Also Published As

Publication number Publication date
US20160060288A1 (en) 2016-03-03
EP2987799A4 (en) 2016-10-05
CN104936971B (zh) 2017-10-13
KR20150143842A (ko) 2015-12-23
EP2987799B1 (en) 2020-04-08
EP2987799A1 (en) 2016-02-24
KR102046415B1 (ko) 2019-12-02
WO2014169462A1 (zh) 2014-10-23
CN104936971A (zh) 2015-09-23
AU2013386732B2 (en) 2018-10-18
JP2016517849A (ja) 2016-06-20
AU2013386732A1 (en) 2015-09-24
JP6356218B2 (ja) 2018-07-11

Similar Documents

Publication Publication Date Title
AU2021269278B2 (en) Lymph directing prodrugs
CN112703003B (zh) 孕烷神经类固醇的脂质前药及其用途
WO2011014661A2 (en) Liver x receptor agonists
WO2023207102A1 (en) Lipid nanoparticles
WO2021159021A1 (en) Lipid prodrugs of neurosteroids
CN106061990A (zh) 一种阿比特龙衍生物及其制备方法和医药用途
CN104684883A (zh) 新型乌索酸衍生物及其制备方法
AU2016415408B2 (en) Rotigotine behenate, and preparation method and use thereof
AU2013386732B2 (en) Ester derivative of 7-alpha-[9-(4,4,5,5,5-pentafluoropentylsulphinyl)nonyl]oestra-1,3,5(10)-triene-3,17beta-diol having antitumour activity and preparation method thereof
CN121443581A (zh) 用于肌肉特异性递送的可电离脂质
CN106432141B (zh) 卡巴他赛药物前体的制备方法和应用
US20120220580A1 (en) Preparation of carotenoid derivatives and their applications
CN104926912B (zh) 甘草次酸衍生物的合成及其用途
KR20240056728A (ko) 치료제를 국소적으로 전달하기 위한 약물 전달 시스템 및 이의 용도
WO2023103929A1 (zh) 氟维司群衍生物及其制备方法和医药用途
EP2987492B1 (en) Use of 7-a-[9-(4,4,5,5,5 - pentafluoro-pentyl-sulfinyl)nonyl]-estra-1,3,5(10)-triene-3,17b-diol and derivatives thereof
CN104558082A (zh) 一种倍氯米松双丙酸酯的合成方法
RU2554475C2 (ru) ИММУНОМОДУЛИРУЮЩЕЕ СРЕДСТВО НА ОСНОВЕ 3-О-ПРОПИОНАТА АЛЛОБЕТУЛЕНОЛА (19β,28-ЭПОКСИ-18α-ОЛЕАНАН-3β-ИЛ И ПРОПИОНАТ)
Zeini et al. SQUALENOYLATED NANOPARTICLE PRODRUGS
KR20220164216A (ko) 신규한 에르고스텐올 유도체 및 이의 용도
HK40084022A (en) Lipid prodrugs of neurosteroids
JPH03133987A (ja) ２‐マイトマイシンｃ‐スクシニル‐１，３‐ジパルミトイルグリセロールおよびその製造法
DK153556B (da) Fremgangsmaade til fremstilling af estere af 9alfa-klor- eller -fluor-16alfa- eller -16beta-metyl-21-desoxyprednisoloner
CN103204897A (zh) 3,12位修饰的蜀羊泉碱衍生物、其制备方法、制剂及其医药用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180416

FZDE Discontinued

Effective date: 20210831